Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Ubrogepant - Allergan

Drug Profile

Ubrogepant - Allergan

Alternative Names: MK-1602; UBRELVY

Latest Information Update: 12 Feb 2020

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Merck & Co
  • Developer Allergan
  • Class Amides; Antimigraines; Cyclopentanes; Fluorine compounds; Piperidines; Pyridines; Pyrrolidines; Small molecules; Spiro compounds
  • Mechanism of Action Calcitonin gene-related peptide receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Registered Migraine

Most Recent Events

  • 23 Dec 2019 Allergan completes a pharmacokinetic drug-drug interaction phase I trial in Migraine in USA (PO) (NCT04179474)
  • 23 Dec 2019 Registered for Migraine in USA (PO)-first global approval
  • 23 Dec 2019 Allergan plans to launch ubrogepant for Migraine in the first quarter of 2020
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top